REFERENCES
- Salem M.M. Hyperparathyroidism in the Hemodialysis Population: A Survey of 612 Patients. Am. J. Kidney Dis. 1997; 29: 862–865
- Malberti F., Corradi B., Cosci P., Calliada F., Marcelli D., Imbasciati E. Long-Term Effects of Intravenous Calcitriol Therapy on the Control of Secondary Hyperparathyroidism. Am. J. Kidney Dis. 1996; 28: 704–712
- Fukagawa M., Kitaoka M., Yi H., Fukuda N., Matsumoto T., Ogata E., Kurokawa K. Serial Evaluation of Parathyroid Size by Ultrasonography is Another Useful Marker for the Long-Term Prognosis of Calcitriol Pulse Therapy in Chronic Dialysis Patients. Nephron. 1994; 68: 221–228
- Quarles L.D., Yohay D.A., Carrol B.A. Prospective Trial of Pulse Oral Versus Intravenous Calcitriol Treatment of Hyperparathyroidism in ESRF. Kidney Int. 1994; 45: 1710–1721
- O’ Doherty M.J., Kettle A.G., Wells P., Collins R.E.C., Coakley A.J. Parathyroid Imaging with Technetium-99m-Sestamibi: Preoperative Localization and Tissue Uptake Studies. J. Nuc. Med. 1992; 33: 313–318
- Piwinica-Worms D., Holman B.L. Noncardiac Application of Hexakis Alkylisonitrile Technetium-99m Complexes. J. Nuc. Med. 1990; 31: 1166–1167
- Piga M., Bolasco P., Satta L., Altieri P., Loi G., Nicolosi A., Tarquini A., Mariotti S. Double-Phase Parathyroid Technetium-99m-MIBI Scintigraphy to Identify Functional Autonomy in Secondary Hyperparathyroidism. J. Nuc. Med. 1996; 37: 565–569
- Ambrossoni P., Heuguerot C., Olaizola I. Can We Use 99mTc-MIBI in Functional Studies of the Parathyroid Gland?. Nephrol. Dial. Transplant. 1998; 13(suppl 3)33–36
- Rassoul Z., Mousa D., Abdur, Rehman M. Serum Parathyroid Hormone Suppression by Intravenous 1,25-dihydroxyvitamin D3 in Patients on Maintenance Hemodialysis. Am. J. Nephrol. 1995; 15: 507–511
- Slatopolsky E., Weerts C., Thielan J., Horst R., Harter H., Martin K.J. Marked Suppression of Secondary Hyperparathyroidism by Intravenous Administration of 1,25-dihydroxycholecalciferol in Uremic Patients. J. Clin. Invest. 1984; 74: 2136–2143
- Dunlay R., Rodriguez M., Felsenfeld A.J., Llach F. Direct Inhibitory Effect of Calcitriol on Parathyroid Function (Sigmoidal Curve) in Dialysis. Kidney Int. 1989; 36: 1093–1098
- Delmez J.A., Tindira C., Grooms P., Dusso A., Windus D.W., Slatopolsky E. Parathyroid Hormone Suppression by Intravenous 1,25-Dihydroxyvitamin D. J. Clin. Invest. 1989; 83: 1349–1355
- Andress D.L., Norris K.C., Coburn J.W., Slatopolsky E.A., Sherrard D.J. Intravenous Calcitriol in the Treatment of Refractory of Osteitis Fibrosa of Chronic Renal Failure. N. Engl. J. Med. 1989; 321: 274–279
- Malberti F., Surian M., Cosci P. Effect of Chronic Intravenous Calcitriol on Parathyroid Function and Set Point of Calcium in Dialysis Patients with Refractory Secondary Hyperparathyroidism. Nephrol. Dial. Transplant. 1992; 7: 822–828
- Dressler R., Laut J., Lynn R.I., Ginsberg N. Long-Term High Dose Intravenous Calcitriol Therapy in End-Stage Renal Disease Patients with Severe Secondary Hyperparathyroidism. Clin. Nephrol. 1995; 43: 324–331
- Fukuda N., Tanaka H., Tominaga Y., Fukagawa M., Kurokawa K., Seino Y. Decreased 1,25-Dihydroxyvitamin D3 Receptor Density is Associated with a More Severe Form of Parathyroid Hyperplasia in Chronic Uremic Patients. J. Clin. Invest. 1993; 92: 1436–1443
- Chesser A.M.S., Carroll M.C., Lightowler C., Macdougal I.C., Britton K.E., Baker L.R.I. Technetium-99m Methoxy Isobutyl Isonitrile (MIBI) Imaging of the Parathyroid Glands in Patients with Renal Failure. Nephrol. Dial. Transplant. 1997; 12: 97–100
- Torregrosa J.V., Palomar M.R., Pons F., Sabater L., Gilabert R., Llovera J., Fernandez-Cruz L. Has Double-Phase MIBI Scintigraphy Usefulness in the Diagnosis of Hyperparathyroidism?. Nephrol. Dial. Transplant. 1998; 13(suppl. 3)37–40